NEOS AB |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.938 SEK | +2.63% |
|
-0.21% | -57.36% |
| 15/04 | Air Astana Partner with Italy-based Neos | MT |
| 22/03 | NeoDynamics AB Announces Appointment of Matilda Salén as Its New Chief Executive Officer | CI |
| Sales 2023 | 751K 68.8K 5.74M | Sales 2024 * | 32M 2.93M 245M | Capitalization | 29.81M 2.73M 228M |
|---|---|---|---|---|---|
| Net income 2023 * | - | Net income 2024 * | - | EV / Sales 2023 | 18.2 x |
| Net cash position 2023 | 2.3M 211K 17.58M | Net cash position 2024 * | 3.9M 357K 29.8M | EV / Sales 2024 * | 0.81 x |
| P/E ratio 2023 * |
-
| P/E ratio 2024 * |
-
| Employees | 9 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 0.93% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +2.63% | ||
| 1 week | -0.21% | ||
| Current month | -1.26% | ||
| 1 month | -1.26% | ||
| 3 months | -44.17% | ||
| 6 months | -71.58% | ||
| Current year | -57.36% |
1 week
0.87
0.94
1 month
0.850.95
Current year
0.852.30
1 year
0.8562.70
3 years
0.85369.00
5 years
0.85650.00
10 years
0.85650.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Director of Finance/CFO | - | 01/22/01 | |
| Chief Tech/Sci/R&D Officer | - | 01/09/01 | |
Magnus Olsen
COO | Chief Operating Officer | - | 01/12/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 01/18/01 | |
Claes Pettersson
BRD | Director/Board Member | 71 | 01/15/01 |
| Director/Board Member | - | 01/21/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/24/29 | 0.938 | +2.63% | 1 059 |
| 26/24/26 | 0.914 | -2.35% | 2,086 |
| 25/24/25 | 0.936 | +4.93% | 4,497 |
| 24/24/24 | 0.892 | -4.90% | 7,998 |
| 23/24/23 | 0.938 | -0.21% | 10,272 |
Delayed Quote Nasdaq Stockholm, April 29, 2024 at 05:01 pm IST
More quotes
NeoDynamics AB (publ) is a Sweden-based company engaged in the medical industry. The Company focuses on developing and commercializing products for breast cancer screening, imaging, and breast cancer treatments. The Companyâs product NeoNavia, enables a pulse biopsy system for ultrasound guided tissue sampling. It consists of a base unit, a handheld driver and three different types of biopsy needles. Each needle type is driven by the pulse technology providing a more controlled needle insertion and precise placement of the needle in the tumour whilst enabling tissue samples from both breasts and lymph nodes. The biopsy system is built on a patented pulse technology, based on research at the Karolinska Institutet in Sweden. NeoNavia is evaluated for breast cancer diagnosis at clinics in United Kingdom, Germany, and Sweden.
Calendar
07/05/2024
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -57.36% | 2.72M | |
| -12.39% | 19.08B | |
| -46.21% | 2.65B | |
| +18.15% | 1.87B | |
| -3.12% | 1.61B | |
| +23.71% | 1.21B | |
| -10.69% | 1.02B | |
| -20.89% | 905M | |
| -4.86% | 716M | |
| -18.10% | 682M |
- Stock Market
- Equities
- NEOD Stock
